AMA0076

AMA0076 is a highly potent, locally acting Rho kinase (ROCK) inhibitor developed for the treatment of glaucoma and ocular hypertension. It is designed to reduce intraocular pressure (IOP) by specifically targeting the main outflow system in the eye, thereby increasing aqueous humor outflow through effects on trabecular meshwork cells. Unlike other ROCK inhibitors, AMA0076 demonstrates minimal side effects such as hyperemia (red eye), which can limit patient compliance with other drugs in this class. The drug exhibits "soft drug" properties—after exerting its effect locally in the eye, it is rapidly converted into an inactive metabolite in surrounding tissues, further minimizing systemic exposure and side effects. Preclinical and clinical studies have shown that AMA0076 effectively lowers IOP with a safety profile superior to existing treatments like latanoprost and bimatoprost[1][2][3][4][5][7].

Other names

sovesudil hydrochloride